Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IVVD

Invivyd Inc

Feb 13 • 04:00PM ET

1.56

+0.03 1.96 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX MRK JNJ NVAX AZN-D GSK GILD SNY

| Held by: VTI XBI VXF ITOT PRFZ LABU BBC IBBQ BIB PWS

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	18.47%	Shs Outstand	277.12M	Perf Week	-1.89%
Market Cap	432.31M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	-0.44%	Shs Float	225.93M	Perf Month	-40.00%
Enterprise Value	350.02M	PEG	-	EPS next Q	-0.08	Inst Own	71.00%	Short Float	9.88%	Perf Quarter	-11.86%
Income	-59.86M	P/S	8.64	EPS this Y	72.67%	Inst Trans	26.34%	Short Ratio	3.32	Perf Half Y	95.17%
Sales	50.04M	P/B	3.59	EPS next Y	41.10%	ROA	-39.76%	Short Interest	22.33M	Perf YTD	-36.84%
Book/sh	0.43	P/C	5.09	EPS next 5Y	48.75%	ROE	-67.94%	52W High	3.07 -49.18%	Perf Year	13.04%
Cash/sh	0.31	P/FCF	-	EPS past 3/5Y	11.20% -24.99%	ROIC	-63.24%	52W Low	0.46 239.13%	Perf 3Y	-17.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.97%	Volatility	10.21% 8.66%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.99	EPS Y/Y TTM	75.73%	Oper. Margin	-124.37%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	332.71%	Profit Margin	-119.63%	RSI (14)	33.93	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.47	EPS Q/Q	87.90%	SMA20	-16.53%	Beta	0.64	Target Price	8.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	41.17%	SMA50	-29.70%	Rel Volume	0.15	Prev Close	1.53
Employees	99	LT Debt/Eq	0.02	Earnings	Nov 06 BMO	SMA200	9.59%	Avg Volume	6.73M	Price	1.56
IPO	Aug 06, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.00% 0.24%	Trades		Volume	1,038,257	Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-25	Initiated	BTIG Research	Buy	$10
Nov-25-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Feb-03-26 07:01AM	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration (GlobeNewswire) +8.05%
Jan-22-26 07:01AM	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention (GlobeNewswire)
Jan-20-26 07:01AM	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 (GlobeNewswire) -8.57%
Jan-14-26 02:13PM	?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 (Insider Monkey) +11.11%
Jan-08-26 07:01AM	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights (GlobeNewswire)
11:13AM	Loading…
Dec-31-25 11:13AM	BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda (Insider Monkey)
Dec-23-25 07:05AM	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
07:01AM	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly) +25.22%
Dec-18-25 01:14AM	Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade (Insider Monkey)
Nov-25-25 07:01AM	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) -5.42%
Nov-24-25 07:01AM	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness (GlobeNewswire)
Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Loading…
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Loading…
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%
Feb-05-25 09:30AM	Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold (GlobeNewswire) +68.80%
Feb-03-25 07:20PM	Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 (Insider Monkey) +196.34% +17.92%
07:00AM	Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population (GlobeNewswire)
06:55AM	Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability (GlobeNewswire)
Jan-27-25 07:01AM	Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -12.85%
Jan-10-25 12:12PM	What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? (Benzinga)
07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC (GlobeNewswire)
Jan-07-25 09:34AM	Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-17-24 06:25AM	Adagio Medical announces Todd Usen as new CEO and director (Medical Device Network) +8.77%
Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)
Nov-14-24 08:20AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.18%
07:05AM	Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:01AM	Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor (GlobeNewswire)
Nov-13-24 07:27AM	Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com) -11.00%
Nov-12-24 08:30AM	Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively (GlobeNewswire)
Nov-06-24 08:01AM	Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire) +12.62%
07:01AM	Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:03AM	Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability (GlobeNewswire) -12.80%
07:01AM	Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants (GlobeNewswire)
Oct-16-24 07:01AM	Invivyd to Present PEMGARDA (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 (GlobeNewswire)
Oct-01-24 07:01AM	Invivyd Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data (GlobeNewswire) -11.75%
Sep-23-24 07:01AM	Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart) (GlobeNewswire)
Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADIMAB, LLC	10% Owner	Dec 23 '25	Proposed Sale	3.00	192,320	577,498		Dec 23 04:23 PM
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	59,344	Aug 19 09:28 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	88,987	Aug 19 09:28 PM
Duke William E.	Chief Financial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:25 PM
Duke William E.	Chief Financial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:25 PM
Green Julie	Chief Human Resources Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:24 PM
Green Julie	Chief Human Resources Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:24 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 19 '25	Sale	0.57	49,402	27,991	84,446	Aug 19 09:21 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '25	Sale	0.65	33,352	21,685	133,848	Aug 19 09:21 PM
Allen Robert D. III	Chief Scientific Officer	Aug 19 '25	Sale	0.57	27,420	15,536	53,068	Aug 19 09:20 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '25	Sale	0.65	18,512	12,037	80,488	Aug 19 09:20 PM
Green Julie	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:55 PM
Andersen Jill	Officer	Aug 18 '25	Proposed Sale	0.71	66,000	46,669		Aug 18 06:54 PM
Allen Robert D. III	Officer	Aug 18 '25	Proposed Sale	0.71	36,631	25,902		Aug 18 06:53 PM
Lee Timothy Edward	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:49 PM
Duke William E.	Officer	Aug 18 '25	Proposed Sale	0.71	39,601	28,002		Aug 18 06:44 PM

Open in Screener

ALEC

Alector Inc

Feb 13 • 04:00PM ET

1.87

-0.03 -1.58 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN IONS VRTX SGMO SAGE ACAD LLY GILD AVXL

| Held by: VTI IWM VXF IWN SCHA VTWO IWC VHT PRFZ IWO

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	30.05%	Shs Outstand	107.45M	Perf Week	-4.59%
Market Cap	204.11M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	-0.93%	Shs Float	76.35M	Perf Month	1.08%
Enterprise Value	-49.12M	PEG	-	EPS next Q	-0.38	Inst Own	64.17%	Short Float	8.56%	Perf Quarter	39.55%
Income	-107.74M	P/S	2.96	EPS this Y	-16.49%	Inst Trans	-13.59%	Short Ratio	5.13	Perf Half Y	-23.98%
Sales	69.05M	P/B	3.48	EPS next Y	30.77%	ROA	-25.31%	Short Interest	6.53M	Perf YTD	19.87%
Book/sh	0.54	P/C	0.70	EPS next 5Y	1.36%	ROE	-121.98%	52W High	3.40 -45.00%	Perf Year	11.98%
Cash/sh	2.67	P/FCF	-	EPS past 3/5Y	-39.73% 6.31%	ROIC	-124.39%	52W Low	0.87 114.94%	Perf 3Y	-80.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-21.40% 36.50%	Gross Margin	86.27%	Volatility	6.38% 6.39%	Perf 5Y	-91.12%
Dividend TTM	-	EV/Sales	-0.71	EPS Y/Y TTM	37.36%	Oper. Margin	-172.76%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.76	Sales Y/Y TTM	12.26%	Profit Margin	-156.03%	RSI (14)	52.05	Recom	3.12
Dividend Gr. 3/5Y	- -	Current Ratio	3.76	EPS Q/Q	21.95%	SMA20	-2.27%	Beta	0.62	Target Price	2.10
Payout	-	Debt/Eq	0.66	Sales Q/Q	-78.75%	SMA50	11.92%	Rel Volume	0.97	Prev Close	1.90
Employees	238	LT Debt/Eq	0.50	Earnings	Nov 06 AMC	SMA200	1.90%	Avg Volume	1.27M	Price	1.87
IPO	Feb 07, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.56% -6.52%	Trades		Volume	1,237,986	Change	-1.58%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-22-25	Downgrade	TD Cowen	Buy → Hold
Oct-22-25	Downgrade	Mizuho	Outperform → Neutral	$1.50
Oct-22-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-22-25	Downgrade	BTIG Research	Buy → Neutral
Jul-28-25	Upgrade	Mizuho	Neutral → Outperform	$3.50
Dec-17-24	Downgrade	Mizuho	Outperform → Neutral	$9 → $2.50
Dec-16-24	Downgrade	Stifel	Buy → Hold	$4
Dec-04-24	Downgrade	BofA Securities	Neutral → Underperform	$9 → $1
Nov-29-24	Reiterated	H.C. Wainwright	Buy	$35 → $7
Nov-26-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$10 → $3
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18

Show Previous Ratings

Feb-12-26 05:45PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Dec-12-25 04:05PM	Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
Dec-01-25 04:05PM	Alector to Participate in the Bank of America CNS Therapeutics Conference (GlobeNewswire) -7.52% -7.32%
Nov-18-25 10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-06-25 06:25PM	Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:29PM	Loading…
05:29PM	Alector: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-25 05:42AM	Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab (Insider Monkey)
Oct-30-25 10:00AM	Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 10:00AM	Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-22-25 07:22AM	Alector dementia drug, partnered with GSK, fails in key study (BioPharma Dive) -49.84%
Oct-21-25 04:05PM	Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update (GlobeNewswire)
Sep-16-25 08:00AM	Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs (GlobeNewswire) -6.76%
Sep-12-25 09:09AM	Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock? (Zacks)
Aug-28-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
09:55AM	Loading…
Aug-22-25 09:55AM	After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright (Zacks) +11.01%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +47.26%
05:09PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:40PM	Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation (Insider Monkey) -6.88%
04:05PM	Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call (GlobeNewswire)
Jun-13-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Jun-03-25 08:00AM	Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +7.25%
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.50%
May-08-25 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +12.50%
04:05PM	Alector Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -9.48%
Apr-21-25 08:50AM	Alector concludes enrolment in Phase II trial of Alzheimers treatment (Clinical Trials Arena) +5.79%
Apr-17-25 08:00AM	Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimers Disease (GlobeNewswire) -5.95%
Mar-28-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
12:32PM	Loading…
Feb-27-25 12:32PM	Q4 2024 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Feb-26-25 05:55PM	Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:53PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 11:01AM	Alector Inc (ALEC) Q4 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call (GlobeNewswire)
Jan-13-25 08:00AM	Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 (GlobeNewswire)
Nov-27-24 06:50AM	Alector price target lowered to $7 from $35 at H.C. Wainwright (TipRanks)
Nov-26-24 09:00AM	Alector stock drops after Alzheimers drug fails in Phase II trial (Clinical Trials Arena) -35.10%
03:44AM	Alector turns to layoffs as Alzheimers drug fails (BioPharma Dive)
Nov-25-24 04:05PM	Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update (GlobeNewswire)
Nov-14-24 04:05PM	Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital (GlobeNewswire) -17.21%
Nov-06-24 05:50PM	Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +7.63%
04:43PM	Alector: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Sep-19-24 08:00AM	Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) (GlobeNewswire) +8.87%
Aug-29-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-23-24 07:19PM	Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC) (GuruFocus.com)
Aug-07-24 06:15PM	Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:11PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 04:05PM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-28-24 08:05AM	Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024 (AAIC ) (GlobeNewswire)
Jul-23-24 07:00AM	Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jun-29-24 08:43PM	Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-20-24 07:00AM	Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform (GlobeNewswire)
Jun-03-24 07:00AM	Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-09-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-08-24 11:55PM	ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:19PM	Alector: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know (Zacks) -8.38%
Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +32.38%
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wong-Sarad Grace	Principal Accounting Officer	Dec 05 '25	Sale	1.21	4,753	5,751	122,982	Dec 08 06:03 PM
GRACE WONG-SARAD	Officer	Dec 05 '25	Proposed Sale	1.21	4,753	5,751		Dec 05 04:09 PM
Wong-Sarad Grace	Principal Accounting Officer	Dec 03 '25	Sale	1.12	8,056	9,019	127,735	Dec 03 09:07 PM
Rosenthal Arnon	Chief Executive Officer	Dec 03 '25	Sale	1.12	104,347	116,827	2,420,040	Dec 03 09:06 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 03 '25	Sale	1.12	41,687	46,673	501,652	Dec 03 09:05 PM
Berkley Neil Lindsay	Chief Bus Ofcr & Interim CFO	Dec 03 '25	Sale	1.12	37,261	41,717	374,309	Dec 03 09:04 PM
Arnon Rosenthal	Officer	Dec 01 '25	Proposed Sale	1.23	92,427	113,685		Dec 01 07:53 PM
Neil L. Berkley	Officer	Dec 01 '25	Proposed Sale	1.23	32,992	40,580		Dec 01 07:50 PM
Grace Wong-Sarad	Officer	Dec 01 '25	Proposed Sale	1.23	7,085	8,715		Dec 01 07:49 PM
Sara Kenkare-Mitra	Officer	Dec 01 '25	Proposed Sale	1.23	36,914	45,404		Dec 01 07:48 PM
Wong-Sarad Grace	Principal Accounting Officer	Sep 02 '25	Sale	2.50	5,910	14,756	103,448	Sep 04 04:33 PM
Berkley Neil Lindsay	Principal Financial Officer	Sep 02 '25	Sale	2.50	15,842	39,554	346,570	Sep 04 04:32 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 02 '25	Sale	2.50	23,638	59,019	543,339	Sep 04 04:29 PM
Rosenthal Arnon	Chief Executive Officer	Sep 02 '25	Sale	2.50	51,562	128,740	2,350,220	Sep 04 04:27 PM
Neil L. Berkley	Officer	Sep 02 '25	Proposed Sale	2.35	15,426	36,251		Aug 29 06:25 PM
Arnon Rosenthal	Officer	Sep 02 '25	Proposed Sale	2.35	50,242	118,069		Aug 29 06:23 PM
Grace Wong-Sarad	Officer	Sep 02 '25	Proposed Sale	2.35	5,717	13,435		Aug 29 06:20 PM
Sara Kenkare-Mitra	Officer	Sep 02 '25	Proposed Sale	2.35	23,019	54,095		Aug 29 06:17 PM
Hammond Paula	Director	Aug 26 '25	Sale	2.36	14,000	32,998	74,909	Aug 27 06:37 PM
PAULA HAMMOND	Director	Aug 26 '25	Proposed Sale	2.36	14,000	32,997		Aug 26 04:07 PM
MARC GRASSO	Officer	Aug 08 '25	Proposed Sale	2.00	76,446	152,892		Aug 08 05:22 PM
Yaffe Kristine	Director	Jun 20 '25	Sale	1.44	1,000	1,440	95,409	Jun 23 04:05 PM
GRASSO MARC	Chief Financial Officer	Jun 02 '25	Sale	1.34	16,488	22,068	296,072	Jun 04 04:21 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 02 '25	Sale	1.34	23,890	31,974	512,252	Jun 04 04:19 PM
Rosenthal Arnon	Chief Executive Officer	Jun 02 '25	Sale	1.34	52,087	69,713	2,414,657	Jun 04 04:18 PM
Sara Kenkare-Mitra	Officer	Jun 02 '25	Proposed Sale	1.33	23,020	30,617		May 30 05:10 PM
Marc Grasso	Officer	Jun 02 '25	Proposed Sale	1.33	15,873	21,111		May 30 05:10 PM
Arnon Rosenthal	Officer	Jun 02 '25	Proposed Sale	1.33	50,242	66,822		May 30 05:10 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 03 '25	Sale	1.47	29,073	42,662	536,142	Mar 05 04:05 PM
Rosenthal Arnon	Chief Executive Officer	Mar 03 '25	Sale	1.47	40,330	59,176	2,466,744	Mar 05 04:05 PM
GRASSO MARC	Chief Financial Officer	Mar 03 '25	Sale	1.47	18,091	26,547	312,560	Mar 05 04:05 PM
Romano Gary	Chief Medical Officer	Mar 03 '25	Sale	1.47	16,306	23,927	332,977	Mar 05 04:05 PM
Arnon Rosenthal	Officer	Mar 03 '25	Proposed Sale	1.64	50,242	82,397		Feb 28 05:05 PM
Gary Romano	Officer	Mar 03 '25	Proposed Sale	1.64	14,306	23,462		Feb 28 05:05 PM
Sara Kenkare-Mitra	Officer	Mar 03 '25	Proposed Sale	1.64	25,516	41,846		Feb 28 05:05 PM
Marc Grasso	Officer	Mar 03 '25	Proposed Sale	1.64	15,873	26,032		Feb 28 05:05 PM

Open in Screener

CYCN

Cyclerion Therapeutics Inc

Feb 13 • 04:00PM ET

1.25

+0.04 3.31 %

Healthcare • Biotechnology • USA • NASD

CYCN Cyclerion Therapeutics Inc daily Stock Chart

Peers: SRPT BMRN EXEL BLUE NBIX TBPH CRBP VKTX RDUS PRQR

| Held by: ONEQ VXF

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	30.85%	Shs Outstand	3.70M	Perf Week	13.64%
Market Cap	4.91M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.31M	Perf Month	-17.76%
Enterprise Value	0.34M	PEG	-	EPS next Q	-	Inst Own	3.66%	Short Float	7.16%	Perf Quarter	-11.97%
Income	-2.20M	P/S	1.72	EPS this Y	-	Inst Trans	3.19%	Short Ratio	0.11	Perf Half Y	-46.35%
Sales	2.85M	P/B	0.48	EPS next Y	-	ROA	-22.77%	Short Interest	0.17M	Perf YTD	-1.57%
Book/sh	2.58	P/C	1.07	EPS next 5Y	-	ROE	-24.80%	52W High	3.79 -67.02%	Perf Year	-58.75%
Cash/sh	1.16	P/FCF	-	EPS past 3/5Y	64.17% 57.72%	ROIC	-23.06%	52W Low	1.03 21.76%	Perf 3Y	-92.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.24% -15.00%	Gross Margin	-	Volatility	11.31% 9.15%	Perf 5Y	-98.55%
Dividend TTM	-	EV/Sales	0.12	EPS Y/Y TTM	64.13%	Oper. Margin	-127.25%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.78	Sales Y/Y TTM	1371.65%	Profit Margin	-77.02%	RSI (14)	44.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.78	EPS Q/Q	-5.73%	SMA20	-4.58%	Beta	0.96	Target Price	4.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	351.03%	SMA50	-13.66%	Rel Volume	0.04	Prev Close	1.21
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	-45.62%	Avg Volume	1.49M	Price	1.25
IPO	Mar 18, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	58,659	Change	3.31%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-21	Initiated	Truist	Buy	$14
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight	$7
Jun-03-19	Initiated	Credit Suisse	Neutral

Jan-05-26 04:01PM	Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression (GlobeNewswire) +41.30%
Nov-10-25 09:16AM	EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network (Benzinga) +10.97%
Sep-23-25 04:01PM	Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company (GlobeNewswire) +7.62%
Dec-17-24 08:08AM	Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth (GlobeNewswire) -7.08%
Aug-07-24 07:00AM	Regina Graul, Ph.D., Promoted to Chief Executive Officer (GlobeNewswire)
07:52AM	Loading…
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +17.98%
May-08-24 08:52AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39% +14.06%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
02:59PM	Loading…
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire) -11.54%
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
07:00AM	Loading…
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62% -5.39%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -5.42%
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90% -5.42%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire) +8.16%
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire) +14.72%
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80% +5.78%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%
Jul-30-20 09:00AM	Cyclerion Therapeutics Completes $24 Million Private Placement (GlobeNewswire) +12.50%
Jul-17-20 07:00AM	Cyclerion Therapeutics Presentation at Biomarkers in Alzheimers Disease Summit (GlobeNewswire)
Jul-06-20 03:17PM	We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate (Simply Wall St.)
Jul-05-20 02:45PM	Should You Buy Cyclerion Therapeutics, Inc. (CYCN)? (Insider Monkey)
Jun-18-20 04:01PM	Cyclerion to Host Webcast Investor Event on July 9, 2020 (GlobeNewswire) +18.04%
May-22-20 07:52AM	The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset (Simply Wall St.) +6.45%
Apr-10-20 07:00AM	Cyclerion Updates Corporate Progress (GlobeNewswire)

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

IVVD

Invivyd Inc

ALEC

Alector Inc

CYCN

Cyclerion Therapeutics Inc

Upgrade your FINVIZ experience